Outcomes in Patients With 4 to 10 Brain Metastases Treated With Dose-Adapted Single-Isocenter Multitarget Stereotactic Radiosurgery: A Prospective Study
Grace J. Kim, John P. Kirkpatrick(Duke University), James E. Herndon(Duke University), Carey K. Anders(Duke University), Tyketra S. Dale, Karen Allen, Peter E. Fecci(University of Colorado Anschutz Medical Campus), Jordan A. Torok(Duke Medical Center), John H. Sampson(Duke University), Junzo Chino(Duke University), Anna Rodrigues, Evan Buckley, Justus Adamson(Duke Medical Center), F Yin(Duke Kunshan University), Zhiheng Wang, William M. Giles, Chris R. Kelsey(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Lam Lay, Scott Floyd(Duke University)
Cited by 25
Related Papers
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
|Journal of Clinical Oncology|2011|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
|The Lancet Oncology|2017|1.1k
Brain metastases
|Nature Reviews Disease Primers|2019|1.1k
Diagnosis-Specific Prognostic Factors, Indexes, and Treatment Outcomes for Patients With Newly Diagnosed Brain Metastases: A Multi-Institutional Analysis of 4,259 Patients
|International Journal of Radiation Oncology*Biology*Physics|2009|984